Continuation of phase II study of 1-(4-amino-2-methylpyrimidine-5-yl)-methyl-3-(2-chloroethyl)-3-nitrosourea hydrochloride (ACNU).
D000328:Adult; D001853:Bone Marrow / Q000187:drug effects; D002986:Clinical Trials as Topic; D004317:Doxorubicin / Q000008:administration & dosage; D004334:Drug Administration Schedule; D004341:Drug Evaluation; D004359:Drug Therapy, Combination; D005472:Fluorouracil / Q000008:administration & dosage; D006801:Humans; D007951:Leukemia, Myeloid / Q000188:drug therapy; D008297:Male; D009369:Neoplasms / Q000188:drug therapy*; D009607:Nitrosourea Compounds / Q000008:administration & dosage / Q000627:therapeutic use* / Q000633:toxicity
D009607:Nitrosourea Compounds; D004317:Doxorubicin; D005472:Fluorouracil